"Mifepristone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.
| Descriptor ID |
D015735
|
| MeSH Number(s) |
D04.210.500.365.415.580
|
| Concept/Terms |
R-38486- R-38486
- R 38486
- RU-486
- RU 486
- RU486
- R38486
- RU-38486
- RU 38486
- RU38486
|
Below are MeSH descriptors whose meaning is more general than "Mifepristone".
Below are MeSH descriptors whose meaning is more specific than "Mifepristone".
This graph shows the total number of publications written about "Mifepristone" by people in this website by year, and whether "Mifepristone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 1 | 2 | 3 |
| 2023 | 1 | 2 | 3 |
| 2024 | 2 | 0 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mifepristone" by people in Profiles.
-
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Res Treat. 2025 May; 211(1):111-119.
-
Exploring Consumer Preferences for Pharmacy Provision of Mifepristone in the Human-centered Design Discovery Phase. Womens Health Issues. 2024 Nov-Dec; 34(6):580-588.
-
Primary Care's Role in Prescribing Mail-Order Mifepristone. JAMA Intern Med. 2024 Aug 01; 184(8):859-860.
-
Pharmacists' experiences dispensing misoprostol and readiness to dispense mifepristone. J Am Pharm Assoc (2003). 2024 Jan-Feb; 64(1):245-252.e1.
-
Mifepristone implementation in primary care: Clinician and staff insights from a pilot learning collaborative. Contraception. 2024 02; 130:110280.
-
ExPAND Mifepristone: Medical Management of Miscarriage and Abortion in FQHCs. Ann Fam Med. 2023 Sep-Oct; 21(5):468.
-
Barriers to abortion provision in primary care in New England, 2019-2020: A qualitative study. Contraception. 2023 01; 117:39-44.
-
Comparison of vaginal and buccal misoprostol after mifepristone for medication abortion through 70 days of gestation: A retrospective chart review. Contraception. 2022 11; 115:62-66.
-
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.
-
Mifepristone restrictions and primary care: Breaking the cycle of stigma through a learning collaborative model in the United States. Contraception. 2021 07; 104(1):24-28.